Back to news

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Globe Newswire•19/11/2026•16:01 ET
0

Key Highlights

  • ➤Atopic dermatitis Phase 2 failed primary and key secondary efficacy endpoints.
  • ➤Celldex discontinued barzolvolimab development in atopic dermatitis.
  • ➤300mg Q4W reduced PP-NRS 29.2% versus placebo’s 19.5%; difference was nonsignificant.
  • ➤Systemic mast cell depletion produced rapid, sustained tryptase suppression at both doses.
  • ➤CSU BLA submission remains planned for 2027; ColdU and SD Phase 3 studies enrolling.

Expert Statements

Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex

“Celldex is leading the exploration of mast cell science to understand the contribution of mast cells to various diseases and how targeted mast cell depletion can best be implemented to improve the lives of patients.”

Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex

“We have delivered best in disease data in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism while also increasing our understanding of which diseases, like atopic dermatitis, might not be primarily driven by mast cells.”

Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex

“We are thankful to the patients and investigators who have played an important role in furthering this science.”

Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex

“We remain focused on delivering on barzolvolimab’s promise for patients and look forward to announcing additional indications for barzolvolimab based on learnings to date, while also advancing our planned 2027 BLA submission in CSU and executing across our Phase 3 studies in CSU, symptomatic dermographism and cold urticaria.”

* Study did not meet key efficacy measures or internal hurdle rate for continued development * Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase * Favorable safety and tolerability demonstrated, consistent with prior studies * BLA submission for barzolvolimab in CSU anticipated in 2027 * Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling * Additional indications for barzolvolimab to be announced by year end HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met. While some benefit from barzolvolimab treatment was observed, these improvements did not meet the Company’s internal hurdle rate for continued development. Data suggest that while mast cells contribute to AD, they are not a primary driver of the disease. Based on these results, Celldex is discontinuing development in AD. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in